Adult patients with moderate atopic dermatitis: Tacrolimus ointment versus pimecrolimus cream

Journal of Drugs in Dermatology

Volumn 7, Issue 12, 2008, Pages 1153-1158

  Abramovits, William ^a   Fleischer Jr , Alan B ^b   Jaracz, Eileen ^c   Breneman, Debra ^d  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; PIMECROLIMUS; TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADMINISTRATION, CUTANEOUS; ADULT; DERMATITIS, ATOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TACROLIMUS;

EID: 60549116393     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483-1494.
2. Beltrani VS, Boguneiwicz M. Atopic dermatitis. Dermatol Online J. 2003;9:1.
3. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118-127.
4. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351:1715-1721. (Pubitemid 28254541)
5. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003;148(suppl 63):3-10.
6. Coghi S, Bortoletto MC, Sampaio SA, et al. Quality of life is severely compromised in adult patients with atopic dermatitis in Brazil, especially due to mental components. Clinics. 2007;62:235-242.
7. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005;53:S70-77.
8. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113:651-657. (Pubitemid 38544154)
9. Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387-393. (Pubitemid 34225403)
10. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-936. (Pubitemid 30304603)
11. Akers WA. Risks of unoccluded topical steroids in clinical trials. Arch Dermatol. 1980;116:786-788. (Pubitemid 10086217)
12. Novartis Pharmaceuticals Corp. Elidel Prescribing Information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/ elidel.pdf. Accessed May 30, 2008.
13. Astellas Pharma US, Inc. Protopic Prescribing Information. Available at: http://www.astellas.us/docs/protopic.pdf. Accessed May 30, 2008.
14. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle- controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol. 1998;102:637-644.
15. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-57.
16. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med. 1997;337:816-821. (Pubitemid 27391631)
17. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44:S28-38.
18. Soter NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44:S39-46.
19. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495-504.
20. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144:788-794. (Pubitemid 32374782)
21. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002;109:547-555. (Pubitemid 34234209)
22. Luger TA, Lahfa M, Fölster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15:169-178. (Pubitemid 39214578)
23. Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a sixmonth study. Dermatology. 2002;205:271-277.
24. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110:e2.
25. Sunderkötter C, Weiss JM, Bextermöller R, et al. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life]. J Dtsch Dermatol Ges. 2006;4:301-306.
26. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005;53:S186-194.
27. Koo JY, Fleischer AB Jr, Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol. 2005;53:S195-205.
28. Fleischer AB Jr, Abramovits W, Breneman D, et al. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatolog Treat. 2007;18:151-157. (Pubitemid 46854833)
29. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator- blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51:515-525. (Pubitemid 39278069)
30. Paller AS, Lebwohl M, Fleischer AB Jr, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52:810-822. (Pubitemid 40614645)
31. Hanifin JM, Reed ML. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18:82-91. (Pubitemid 47122151)
32. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;Suppl 92:44-47.
33. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18. (Pubitemid 32098039)
34. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96-102. (Pubitemid 38234012)
35. Bigby M. Tacrolimus and pimecrolimus for atopic dermatitis: where do they fit in? Arch Dermatol. 2006;142:1203-1205. (Pubitemid 44414404)
36. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330:516.